Additionally in the RNA-seq data, 16 of the 25 potentially druggable genes, including CDKN1A, TERT, CCND1, and INSR were differentially expressed in RCC compared to normal kidney cells, indicating suitability for inhibitors or agonists (Supplementary Data 5). This evidence concerns the gene INSR and renal cell carcinoma.